Cargando…

Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility

Categorization of patients with COPD as reversible or nonreversible to a bronchodilator may change over time. This post hoc analysis aimed to determine if an individual’s reversibility, when treated as a continuous variable, could predict his/her future response to two short-acting bronchodilators:...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascoe, Steven, Wu, Wei, Zhu, Chang-Qing, Singh, Dave
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010081/
https://www.ncbi.nlm.nih.gov/pubmed/27621609
http://dx.doi.org/10.2147/COPD.S108723
_version_ 1782451625709797376
author Pascoe, Steven
Wu, Wei
Zhu, Chang-Qing
Singh, Dave
author_facet Pascoe, Steven
Wu, Wei
Zhu, Chang-Qing
Singh, Dave
author_sort Pascoe, Steven
collection PubMed
description Categorization of patients with COPD as reversible or nonreversible to a bronchodilator may change over time. This post hoc analysis aimed to determine if an individual’s reversibility, when treated as a continuous variable, could predict his/her future response to two short-acting bronchodilators: albuterol and ipratropium. The analysis was completed using data from a 4-week, randomized, open-label, two-period crossover study (NCT01691482; GSK study DB2114956). Patients received albuterol (doses: UK =4×100 μg/puff; US =4×90 μg/puff) followed 1 hour later by ipratropium (4×20 μg/puff) or vice versa during treatment Period 1. The order of treatments was reversed during Period 2. Predefined efficacy end points included pre- and post-bronchodilator forced expiratory volume in 1 second. The correlation coefficient between bronchodilator response on Days 1 and 10 was investigated, as well as the correlation between treatment response on Day 1 and the mean treatment response on Days 5–10, for each individual patient. Bronchodilator response to albuterol on Day 1 was strongly correlated with that on Day 10 (r=0.64; n=53). The correlation coefficient of bronchodilator treatment response on Day 1 and Days 5–10 was 0.78 (P<0.001; n=53) and 0.76 (P<0.001; n=54) for albuterol and ipratropium, respectively. A single measurement of the initial bronchodilator response to albuterol or ipratropium was, therefore, highly correlated with the subsequent mean bronchodilator response over 5–10 days, demonstrating its potential usefulness for future treatment decisions.
format Online
Article
Text
id pubmed-5010081
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50100812016-09-12 Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility Pascoe, Steven Wu, Wei Zhu, Chang-Qing Singh, Dave Int J Chron Obstruct Pulmon Dis Original Research Categorization of patients with COPD as reversible or nonreversible to a bronchodilator may change over time. This post hoc analysis aimed to determine if an individual’s reversibility, when treated as a continuous variable, could predict his/her future response to two short-acting bronchodilators: albuterol and ipratropium. The analysis was completed using data from a 4-week, randomized, open-label, two-period crossover study (NCT01691482; GSK study DB2114956). Patients received albuterol (doses: UK =4×100 μg/puff; US =4×90 μg/puff) followed 1 hour later by ipratropium (4×20 μg/puff) or vice versa during treatment Period 1. The order of treatments was reversed during Period 2. Predefined efficacy end points included pre- and post-bronchodilator forced expiratory volume in 1 second. The correlation coefficient between bronchodilator response on Days 1 and 10 was investigated, as well as the correlation between treatment response on Day 1 and the mean treatment response on Days 5–10, for each individual patient. Bronchodilator response to albuterol on Day 1 was strongly correlated with that on Day 10 (r=0.64; n=53). The correlation coefficient of bronchodilator treatment response on Day 1 and Days 5–10 was 0.78 (P<0.001; n=53) and 0.76 (P<0.001; n=54) for albuterol and ipratropium, respectively. A single measurement of the initial bronchodilator response to albuterol or ipratropium was, therefore, highly correlated with the subsequent mean bronchodilator response over 5–10 days, demonstrating its potential usefulness for future treatment decisions. Dove Medical Press 2016-08-29 /pmc/articles/PMC5010081/ /pubmed/27621609 http://dx.doi.org/10.2147/COPD.S108723 Text en © 2016 Pascoe et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Pascoe, Steven
Wu, Wei
Zhu, Chang-Qing
Singh, Dave
Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
title Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
title_full Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
title_fullStr Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
title_full_unstemmed Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
title_short Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
title_sort bronchodilator reversibility in patients with copd revisited: short-term reproducibility
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010081/
https://www.ncbi.nlm.nih.gov/pubmed/27621609
http://dx.doi.org/10.2147/COPD.S108723
work_keys_str_mv AT pascoesteven bronchodilatorreversibilityinpatientswithcopdrevisitedshorttermreproducibility
AT wuwei bronchodilatorreversibilityinpatientswithcopdrevisitedshorttermreproducibility
AT zhuchangqing bronchodilatorreversibilityinpatientswithcopdrevisitedshorttermreproducibility
AT singhdave bronchodilatorreversibilityinpatientswithcopdrevisitedshorttermreproducibility